Klein v. CENTRAL FLORIDA INVESTMENTS, INC.

642 F. Supp. 2d 1374, 2009 U.S. Dist. LEXIS 71122, 2009 WL 2477305
CourtDistrict Court, S.D. Florida
DecidedAugust 12, 2009
DocketCase 08-80358-CIV
StatusPublished

This text of 642 F. Supp. 2d 1374 (Klein v. CENTRAL FLORIDA INVESTMENTS, INC.) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Klein v. CENTRAL FLORIDA INVESTMENTS, INC., 642 F. Supp. 2d 1374, 2009 U.S. Dist. LEXIS 71122, 2009 WL 2477305 (S.D. Fla. 2009).

Opinion

OPINION AND ORDER

KENNETH A. MARRA, District Judge.

This cause is before the Court upon Plaintiffs Motion for Partial Summary Judgment (DE 27). The motion is fully briefed and ripe for review. The Court held oral argument on the motion on June 18, 2009. The Court has carefully considered the motion and is otherwise fully advised in the premises.

I. Background

The undisputed facts are as follows: 1

Plaintiff Terry Klein is a New York resident who is the owner of Bluegreen common stock and has been the owner of Bluegreen common stock at all relevant times. (Terry Klein Aff. ¶ 2, Ex. A, DE 27.) Bluegreen, a nominal defendant herein, is a Massachusetts corporation with its principal place of business in Boca Raton, Florida. (Def. Answer ¶ 2.) Defendant Central Florida Investments, Inc. (“CFI”) is a Florida corporation. Defendant David A. Siegel Revocable Trust (the “Siegel Trust”) is a revocable trust established by defendant David A. Siegel (“Siegel”). The Siegel Trust owns 100% of the voting shares of CFI. Siegel is the President and sole director of CFI and the sole trustee of the Siegel Trust. All of the defendants operate out of the same business address in Orlando, Florida. (Def. Answer ¶ 2.)

Starting in 2001, CFI began acquiring stock in Bluegreen. (David Crabtree Aff. ¶ 3, Ex. A, DE 41.) CFI initially acquired shares of Bluegreen’s common stock on the open market and then by writing and selling put options. (Crabtree Aff. ¶ 4.) Before it began writing put option contracts, CFI’s interests in Bluegreen did not require disclosure under applicable federal securities laws. (Crabtree Aff. ¶ 5.) However, as a consequence of CFI’s purchase of Bluegreen stock by virtue of the exercise of puts by other owners of Bluegreen stock, on July 10, 2006, CFI’s holdings increased to 2,349,800 shares, representing 7.7% of the outstanding common stock of Bluegreen. (Crabtree Aff. ¶ 6.)

Because by July 20, 2006 it had for the first time passed the 5% disclosure threshold, CFI timely filed a Section 13D with the Securities and Exchange Commission (“SEC”) disclosing its holdings. This filing was timely amended on August 9, 2006 and again on August 22, 2006, to reflect the additional shares of CFI purchased as the put contracts it wrote were exercised. (Crabtree Aff. ¶ 7.)

*1376 On July 27, 2006, the Bluegreen Board adopted a Shareholders’ Rights Plan (the “Poison Pill”) targeting CFI, the effect of which, if implemented would be to greatly dilute CFI’s proportionate interest in Bluegreen. (Bluegreen Corporation Form 8-K, Ex. B., DE 41.)

The essence of the Poison Pill is that it:

[I]mpose[s] a significant penalty upon any person or group which acquires beneficial ownership of 15% or more of the Company’s outstanding common stock without the prior approval of the Board of Directors. (Bluegreen Corporation Form 8-K.)

The Poison Pill was designed to apply only to CFI, inasmuch as it exempted out:

The Company, its subsidiaries, employee benefit plans of the Company or any of its subsidiaries, and any entity holding common stock for or pursuant to the terms of any such employee benefit plan will be excepted, as well as Levitt Corporation, its affiliates, successors and assigns. (Blue-green Corporation Form 8-K.)

The Poison Pill specified its purpose:

The Board of Directors is taking this action in response to the filing on July 20, 2006 of a Schedule 13D with the Securities and Exchange Commission disclosing that David A. Siegel, individually, through the David A. Siegel Revocable Trust and through a company he controls, Central Florida Investments, Inc., recently acquired approximately 2,349,800 shares of the Company’s common stock. Additionally, Mr. Siegel and his affiliates disclosed that they have sold put contracts with varying expiration dates which, if exercised in full, could result in Mr. Siegel and his affiliates owning 9,791,900 shares, or approximately 32.1% of the Company’s common stock. (Bluegreen Corporation, Form 8-K.)

The Poison Pill was triggered if CFI became the beneficial owner of 15% or more of the outstanding Bluegreen stock. At such time the company granted all shareholders, other than CFI, the right to purchase additional shares of Bluegreen common stock at 50% of the then current market price. If the rights were exercised, it would effectuate a substantial dilution of CFI’s dilution in Bluegreen. (Blue-green Corporation Form 8-K.) At this time, shares of Bluegreen stock were trading at around $11.86, while the put options CFI wrote required that CFI pay $12.50 per share. (Crabtree Aff. ¶ 8.)

Also on July 27, 2006, Bluegreen issued the following press release: “The Board of Directors is taking this action in response to the recent filing of a Schedule 13D with the Securities and Exchange Commission disclosing that David A. Siegel, individually, and through a company he controls, [CFI] recently acquired approximately 2,349,800 shares of the Company’s common stock.” (Bluegreen Corporation Form 8-K; Bluegreen Press Release, Exhibit 99.1, Ex. C, DE 41.)

The Poison Pill, when triggered, diluted only CFI’s ownership interest while allowing all other shareholders to effectively double their holdings at a bargain basement price. (Bluegreen Corporation Form 8-K.) The Poison Pill did not affect the holdings of Levitt Corp., a publicly-traded corporation that is the largest holder of Bluegreen stock and which, at that time, held 31% of Bluegreen’s common stock or 9.5 million shares. (Bluegreen Corporation Form 8-K.) Once the Poison Pill was triggered, namely, when CFI acquired a 15% interest in Bluegreen, the only way CFI could avoid the Poison Pill’s automatic dilution was by divesting itself of approximately 5 million shares within sixty days. (Bluegreen Corporation Form 8-K.)

Thereafter, additional shares were put to CFI, bringing CFI’s total holdings in Bluegreen to 9,632,400 shares, or approxi *1377 mately 31.57% of Bluegreen’s stock. (Crabtree Aff. ¶ 9.) Since these shares were obtained by CFI as a result of puts that existed and were in the open market when the Poison Pill was adopted, effectively the poison pill was already triggered when it was adopted. (Bluegreen Corporation Form 8-K.) CFI did not receive advance notice of the Poison Pill and, since CFI could not control the exercise of the puts it had written, CFI could not avoid triggering it. (Crabtree Aff. ¶ 10.)

The same day it adopted the Poison Pill, Bluegreen also sued CFI in the United States District Court for the Southern District of Florida, (the “Bluegreen Litigation”). (Complaint in Bluegreen Corporation v. David A. Siegel, David A. Siegel Revocable Trust and Central Florida Investments, Inc., United States District Court for the Southern District of Florida Case No. 06-80718, Ex. D, DE 41.) Blue-green sued CFI under three theories: (1) alleged violations of Section 13(d) of the Exchange Act; (2) alleged violations of the Florida Securities and Investor Protection Act; and (3) declaratory judgment to confirm that Bluegreen’s Board of Directors was justified in adopting the Poison Pill. {Id.)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
642 F. Supp. 2d 1374, 2009 U.S. Dist. LEXIS 71122, 2009 WL 2477305, Counsel Stack Legal Research, https://law.counselstack.com/opinion/klein-v-central-florida-investments-inc-flsd-2009.